Katrin Schlack

1.1k total citations
51 papers, 551 citations indexed

About

Katrin Schlack is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Katrin Schlack has authored 51 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 15 papers in Surgery. Recurrent topics in Katrin Schlack's work include Prostate Cancer Treatment and Research (24 papers), Renal cell carcinoma treatment (15 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Katrin Schlack is often cited by papers focused on Prostate Cancer Treatment and Research (24 papers), Renal cell carcinoma treatment (15 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Katrin Schlack collaborates with scholars based in Germany, United States and Switzerland. Katrin Schlack's co-authors include Martin Boegemann, Kambiz Rahbar, Robert Seifert, Matthias Weckesser, Katharina Kessel, Andres Jan Schrader, Laura‐Maria Krabbe, Julie Steinestel, Martin Bögemann and Michael Schäfers and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Katrin Schlack

38 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katrin Schlack Germany	12	405	282	133	119	96	51	551
Katharina Kessel Germany	14	448 1.1×	390 1.4×	188 1.4×	90 0.8×	119 1.2×	16	638
Joshua James Morigi Australia	6	541 1.3×	435 1.5×	80 0.6×	116 1.0×	53 0.6×	15	725
Bernhard Grubmüller Austria	12	615 1.5×	434 1.5×	120 0.9×	81 0.7×	40 0.4×	33	681
Monika Looijen-Salamon Netherlands	12	386 1.0×	190 0.7×	199 1.5×	175 1.5×	50 0.5×	20	613
Chris Bangma Netherlands	12	336 0.8×	73 0.3×	105 0.8×	72 0.6×	122 1.3×	28	547
Keita Tamura Japan	15	419 1.0×	79 0.3×	193 1.5×	112 0.9×	184 1.9×	69	644
Séverine Banek Germany	15	290 0.7×	99 0.4×	162 1.2×	74 0.6×	249 2.6×	65	592
Kilian Schiller Germany	13	825 2.0×	573 2.0×	167 1.3×	112 0.9×	90 0.9×	35	969
Khaldoun Kerrou France	11	111 0.3×	159 0.6×	121 0.9×	87 0.7×	102 1.1×	22	424
Christoph A. von Klot Germany	13	477 1.2×	288 1.0×	72 0.5×	110 0.9×	146 1.5×	20	653

Countries citing papers authored by Katrin Schlack

Since Specialization

Citations

This map shows the geographic impact of Katrin Schlack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katrin Schlack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katrin Schlack more than expected).

Fields of papers citing papers by Katrin Schlack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katrin Schlack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katrin Schlack. The network helps show where Katrin Schlack may publish in the future.

Co-authorship network of co-authors of Katrin Schlack

This figure shows the co-authorship network connecting the top 25 collaborators of Katrin Schlack. A scholar is included among the top collaborators of Katrin Schlack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katrin Schlack. Katrin Schlack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paffenholz, Pia, Jozefina Casuscelli, Emily Rinderknecht, et al.. (2025). Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.. Journal of Clinical Oncology. 43(5_suppl). 488–488. 1 indexed citations

Darr, Christopher, Jens Bedke, Philipp Ivanyi, et al.. (2025). Treatment of Advanced or Metastatic Urothelial Cancer. Oncology Research and Treatment. 49(1-2). 4–12.

Casuscelli, Jozefina, Thomas Büttner, Christopher Darr, et al.. (2025). Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).. Journal of Clinical Oncology. 43(5_suppl). 715–715.

Seifert, Keith A., et al.. (2025). Molecular analysis of androgen receptor splice variant AR-V3 reveals eminent ambiguity regarding activity and clinical utility. Cancer Cell International. 25(1). 316–316.

Rahbar, Kambiz, Katrin Schlack, & Martin Bögemann. (2025). Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study. BMC Cancer. 25(1). 1159–1159.

Krabbe, Laura-Maria, et al.. (2024). Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer. 22(5). 102164–102164. 1 indexed citations

Shore, Neal D., Michael S. Broder, Pedro C. Barata, et al.. (2024). Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy. European Urology Oncology. 8(1). 94–104. 1 indexed citations

Paffenholz, Pia, Katrin Schlack, Marco J. Schnabel, et al.. (2024). Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination.. Journal of Clinical Oncology. 42(4_suppl). 436–436.

Schindler, Philipp, Martin Bögemann, Katrin Schlack, et al.. (2024). Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET. Cancer Imaging. 24(1). 126–126. 2 indexed citations

10.

Klümper, Niklas, Thomas Büttner, Alexander Höllein, et al.. (2024). Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.. Journal of Clinical Oncology. 42(4_suppl). 553–553. 1 indexed citations

11.

Uhlig, Annemarie, Lothar Bergmann, Martin Bögemann, et al.. (2024). Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review. Urologia Internationalis. 108(3). 198–210. 2 indexed citations

12.

Schlack, Katrin, et al.. (2023). Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe. European Urology Open Science. 57. S152–S153.

13.

Steinestel, Julie, Stefan Duensing, Laura‐Maria Krabbe, et al.. (2023). Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer. Biomarker Research. 11(1). 37–37. 8 indexed citations

14.

Uhlig, Annemarie, Johannes Uhlig, Thomas Fischer, et al.. (2023). Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry. 7(1). 37–48. 2 indexed citations

15.

Seifert, Robert, Katharina Kessel, Katrin Schlack, et al.. (2021). Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Theranostics. 11(17). 8143–8151. 23 indexed citations

16.

Schlack, Katrin, Laura‐Maria Krabbe, Kambiz Rahbar, et al.. (2021). ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. Translational Andrology and Urology. 10(10). 3986–3999. 8 indexed citations

17.

Seifert, Robert, Katharina Kessel, Katrin Schlack, et al.. (2020). Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. European Journal of Nuclear Medicine and Molecular Imaging. 47(9). 2106–2112. 38 indexed citations

18.

Kessel, Katharina, Robert Seifert, Michael Schäfers, et al.. (2019). Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving ¹⁷⁷Lu-PSMA-617. Theranostics. 9(17). 4841–4848. 64 indexed citations

19.

Schlack, Katrin, Martin Boegemann, Julie Steinestel, Andres Jan Schrader, & Laura‐Maria Krabbe. (2016). The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Review of Anticancer Therapy. 16(3). 255–271. 27 indexed citations

20.

Boegemann, Martin, Katrin Schlack, Joachim Gerß, et al.. (2016). Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate. PLoS ONE. 11(9). e0161959–e0161959. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact